A major new study—the Stratification and Treatment in Early Psychosis (STEP) trial—is set to investigate CBD as a potential treatment for psychosis on a larger scale than ever before. Led by Philip McGuire, MD, professor of psychiatry at Oxford University, STEP will involve 1,000 participants across 30 sites in 10 countries 🌍, making it one of the most ambitious trials of its kind.
🔬 Why it matters:
✅ CBD has shown promise in early studies for psychosis, but large-scale evidence is needed.
✅ STEP will combine three smaller trials to explore effectiveness, biomarkers, and precision treatment approaches.
✅ Nature Medicine named it one of 11 studies that will shape medicine in 2025.
🚀 Could CBD redefine psychosis treatment? The results could change the landscape of psychiatric care. Stay tuned!